12:00 AM
 | 
Sep 10, 2012
 |  BC Week In Review  |  Company News  |  Deals

Medivir, Novadex Pharmaceuticals deal

Medivir acquired from Novadex a portfolio of preclinical antiviral programs, including nucleotide polymerase inhibitors. Medivir said the portfolio includes IP and prodrug technologies that can...

Read the full 104 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >